National Taiwan Ocean University Institutional Repository:Item 987654321/37672
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 28611/40652
Visitors : 779927      Online Users : 46
RC Version 4.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Adv. Search

Please use this identifier to cite or link to this item:

Title: Response to Sorafenib in a Patient with Metastatic Xp11 Translocation Renal Cell Carcinoma
Authors: Ming-Mo Hou;Jia-Juan Hsieh;Nai-Jen Chang;Hsuan-Ying Huang;Hung-Ming Wang;Cheng-Keng Chuang;Todd HsuJohn Wen-Cheng Chang
Contributors: 國立台灣海洋大學:生命科學系
Date: 2010-11
Issue Date: 2016-04-11T02:46:53Z
Publisher: Clinical Drug Investigation
Abstract: Abstract:Sorafenib, a multikinase inhibitor of tumour-cell proliferation and angiogenesis, has been shown to have a role in the treatment of metastatic renal cell carcinoma (RCC). Xp11 translocation carcinoma is a rare subtype of RCC. We report an 18-year-old male patient with metastatic Xp11 translocation RCC who was responsive to sorafenib treatment. Six weeks after commencement of treatment with sorafenib, a CT scan of the patient showed increased central necrosis of the kidney mass and para-aortic lymph nodes as well as regression of the lung and pleural masses. The patient had a progression-free survival of 12 months, and overall survival of 15 months. The most severe adverse effects were grade 3 dermatitis and grade 3 anaemia. This case has demonstrated for the first time that sorafenib is active against Xp11 translocation RCC.
Relation: 30(11),pp.799-804
Appears in Collections:[Department of Life Science] Periodical Articles

Files in This Item:

File Description SizeFormat

All items in NTOUR are protected by copyright, with all rights reserved.


著作權政策宣告: 本網站之內容為國立臺灣海洋大學所收錄之機構典藏,無償提供學術研究與公眾教育等公益性使用,請合理使用本網站之內容,以尊重著作權人之權益。
網站維護: 海大圖資處 圖書系統組
DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback